Sure! Here’s the translation to American English:
Theriva Biologics, a clinical-stage company dedicated to developing treatments for cancer and related diseases, has announced the terms of a public offering aimed at acquiring up to 6,818,180 shares of common stock and warrants. The established price for this offering is $1.10 per share and accompanying warrant, and total proceeds are expected to reach approximately $7.5 million. The warrants will offer an exercise price of $1.10 per share and may be exercised immediately, with an expiration period of five years from the date of issuance.
The closing of the offering is scheduled for May 8, 2025, although it is subject to customary closing conditions. The funds generated from this offering will primarily be used to increase working capital and to finance research and development activities, as well as to expand production capacity. While the company does not rule out the possibility of making investments in other products or technologies, there are currently no formal commitments regarding such direction.
A.G.P./Alliance Global Partners will act as the exclusive placement agent for this offering. The securities will be offered under a registration statement filed with the Securities and Exchange Commission (SEC), which was declared effective on May 7, 2025. The offering will be conducted solely through a prospectus included in the registration statement.
Theriva Biologics is focused on developing a platform of oncolytic adenoviruses for intravenous administration and has made progress with several treatment candidates that are in clinical phases. The company emphasizes that this announcement does not constitute an offer to sell or a solicitation to buy securities, which is prohibited in jurisdictions where they are not properly registered.
via: MiMub in Spanish
